Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Cash from Operations came in at 2514000000.0 in Q1 2026, down 39.77% year-on-year from 4174000000.0 in Q1 2025, and down 65.6% quarter-over-quarter from 7309000000.0 in Q4 2025.

Johnson & Johnson (JNJ) Cash from Operations (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Cash from Operations across 18 years of filings, most recently posting 2514000000.0 for Q1 2026.

  • Cash from Operations for Q1 2026 came in at 2514000000.0, down 39.77% year-over-year; the trailing twelve-month figure through Mar 2026 was 22870000000.0 (down 7.72% YoY), and the FY2025 annual result was 24530000000.0, up 1.09% from the prior year.
  • Cash from Operations came in at 2514000000.0 for Q1 2026 at Johnson & Johnson, down from 7309000000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 9169000000.0 in Q3 2025 to a low of 2514000000.0 in Q1 2026.
  • The 5-year median for Cash from Operations is 4182000000.0 (2023), against an average of 5439733333.33.
  • Across the five-year window, Cash from Operations jumped 123.63% in 2023 and slumped 39.77% in 2026, its largest moves.
  • Johnson & Johnson's Cash from Operations stood at 3979000000.0 in 2022, then soared by 97.61% to 7863000000.0 in 2023, then decreased by 11.19% to 6983000000.0 in 2024, then grew by 4.67% to 7309000000.0 in 2025, then tumbled by 65.6% to 2514000000.0 in 2026.
  • The last three Cash from Operations figures came in at 2514000000.0 (Q1 2026), 7309000000.0 (Q4 2025), and 9169000000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 1.82 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 5.33 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 2.51 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 3.83 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn 3.92 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 2.19 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 2.54 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 2.62 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 1.10 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 2.51 Bn
Mar 29, 2026 2.51 Bn
Dec 28, 2025 7.31 Bn
Dec 28, 2025 7.31 Bn
Sep 28, 2025 9.17 Bn
Sep 28, 2025 9.17 Bn
Jun 29, 2025 3.88 Bn
Jun 29, 2025 3.88 Bn
Mar 30, 2025 4.17 Bn
Mar 30, 2025 4.17 Bn
Dec 29, 2024 6.98 Bn
Dec 29, 2024 6.98 Bn
Sep 29, 2024 7.99 Bn
Sep 29, 2024 7.99 Bn
Jun 30, 2024 5.63 Bn
Jun 30, 2024 5.63 Bn
Mar 31, 2024 3.66 Bn
Mar 31, 2024 3.66 Bn
Dec 31, 2023 7.86 Bn
Dec 31, 2023 7.86 Bn